Phenol-containing antagonists of the CXCR2 receptor

Bibliography

• Tsuruma T, Yagihashi A, Hirata K, et al. Evaluation of plasma CXCL8 (CINC) concentration during ischemia and after reperfusion in the small intestine. Transplant Proc 1996;28:1917-8
   PubMedGoogle Scholar
• Frieri M, Therattil JM, Zitt M, et al. Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor. Ann Allergy Asthma Immunol 1998;81:331-6
   PubMedGoogle Scholar
• Takayama F, Miyazaki T, Aoyama I, et al. Involvement of interleukin-8 in dialysis-related arthritis. Kidney Int 1998;53:1007-13
   PubMedGoogle Scholar
• Hay DWP, Sarau HM. Interleukin-8 Receptor Antagonists in Pulmonary Diseases. Curr Opin Pharmacol 2001;1:242-7
   PubMedGoogle Scholar
• Bizzarri C, Allegretti M, Di Bitondo R, et al. Pharmacological inhibition of interleukin-8 (CXCL8) as a new approach for the prevention and treatment of several human diseases. Curr Med Chem Anti-Inflamm Anti-Allergy Agents 2003;2:67-79
   Google Scholar
• Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: Implications for therapy. Am J Resp Med 2002;1:19-25
   PubMedGoogle Scholar
• Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997;112:505-10
   PubMed Web of Science ®Google Scholar
• Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin receptor. Science 1991;253:1280-3
   PubMed Web of Science ®Google Scholar
• Holmes WE, Lee J, Kuang WJ, et al. Structure and functional expression of a human interleukin-8 receptor. Science 1991;253:1278-80
   PubMed Web of Science ®Google Scholar
• Walz A, Burgener R, Car B, et al. Structure and Neutrophil-activating Properties of a Novel Inflammatory Peptide (ENA-78) with Homology to Interleukin-8. J Exp Med 1991;174:1355-62
   PubMed Web of Science ®Google Scholar
• Wolf M, Delgado MB, Jones SA, et al. Granulocyte chemotactic protein 2 act via both CXCL8 receptors, CXCR1 and CXCR2. Eur J Immunol 1998;28:164-70
   PubMed Web of Science ®Google Scholar
• Li JJ. Small Molecule Interleukin-8 Modulators. Expert Opin Ther Patents 2001;11:1905-10
   Web of Science ®Google Scholar
• Widdowson, KL. Phenyl urea interleukin-8 receptor antagonists for treatment of interleukin-8-mediated diseases, and preparation thereof. WO199749286; 1997
   Google Scholar
• Widdowson K, Veber DF, Jurewicz AJ, et al. In: Ramage R, editor, Peptides 1996. Mayflower Scientific Ltd; 1998. p. 87-92
   Google Scholar
• Busch-Petersen J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr Top Med Chem 2006;6:1345-52
   PubMedGoogle Scholar
• Jin Q, McCleland BW, Palovich MR, et al. Preparation of hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists. WO2000035442; 2000
   Google Scholar
• Jin Q, Nie H, McCleland BW, et al. Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor. Bioorg Med Chem Lett 2004;14:4375-8
   PubMed Web of Science ®Google Scholar
• Benson GM, Grimsditch DC, Piercy V, et al. A CXCR2 antagonist, SB-332235, reduces atherosclerosis in LDL receptor deficient mice. Atherosclerosis 2005;181:419
   Google Scholar
• Stevenson CS, Coote K, Webster R, et al. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol 2005;288:L514-22
   PubMed Web of Science ®Google Scholar
• Busch-Petersen J, Palovich MR, Widdowson KL. Diarylurea derivatives, particularly N-[2-hydroxy-3-(1-piperazinylsulfonyl)phenyl]-N′-(halophenyl)ureas, useful as IL-8 receptor antagonists, and their preparation, pharmaceutical compositions, and use in the treatment of chemokine-mediated diseases. WO2004039775; 2004
   Google Scholar
• Busch-Petersen J. Preparation of heterocyclylsulfonylhydroxyphenylureas as interleukin-8 (IL-8) receptor antagonists. WO2007124423; 2007
   Google Scholar
• Busch-Petersen J. Preparation of N-sulfonylphenyl-N′-(hetero)arylureas as antagonists of chemokines, particular interleukin 8 (IL-8). US2007249672; 2007
   Google Scholar
• Salmon M, Carpenter CJ, DeHaas CJ, et al. Inhibition of LPS-induced neutrophil recruitment in the lungs correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933. European Respiratory Symposium, September 2004. Eur Resp J 2004;24(Suppl 48):218s
   Google Scholar
• Carpenter DC, Rumsey WM, Busch-Petersen J, et al. The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood. European Respiratory Symposium, September 2004. Eur Resp J 2004;24(Suppl 48):218s
   Google Scholar
• Palovich MR, Widdowson KL, Nie H. Preparation of aminosulfonylpyridine phenylurea derivatives as interleukine-8 receptor antagonists. WO2001076530; 2001
   Google Scholar
• Chao J, Taveras AG, Aki CJ, et al. Preparation of sulfonylthiophene-substituted ureas and analogs as CXCR1 and CXCR2 chemokine antagonists. WO2005113534; 2005
   Google Scholar
• Palovich MR, Widdowson KL, Nie H. Preparation of (aminosulfonyl)phenyl phenyl guanidine derivs. as IL-8 antagonists in the treatment of cytokine-mediated diseases and injuries. WO2001072960; 2001
   Google Scholar
• Nie H, Widdowson KL, Palovich MR, et al. Bioorg Med Chem Lett 2006;16:5513-6
   PubMed Web of Science ®Google Scholar
• Palovich MR, Widdowson KL, Nie H. Preparation of sulfonamido substituted diphenyl thioureas as IL-8 receptor antagonists. WO2001068033; 2001
   Google Scholar
• Palovich MR, Weinstock J, Widdowson KL. Diphenyl sulfamido compound interleukin-8 receptor antagonists for therapeutic use. WO2001064165; 2001
   Google Scholar
• Palovich MR, Weinstock J, Widdowson KL. N,N′-diphenylphosphorodiamidates as IL-8 receptor antagonists. WO2001064691; 2001
   Google Scholar
• Palovich MR, McCleland B, Bi G, et al. Preparation of dianilino squarates as IL-8 receptor antagonists. WO2001092202; 2001
   Google Scholar
• McCleland B, Palovich MR, Widdowson KL. Preparation of sulfonamide squaramides as Il-8 receptor antagonists. WO2002057230; 2002
   Google Scholar
• Palovich MR, Widdowson KL. Amide squaramides as IL-8 receptor antagonists. WO2002067919; 2002
   Google Scholar
• Taveras AG, Aki CJ, Bond RW, et al. Preparation of 3,4-diaminocyclobutene-1,2-diones as CXC chemokine receptor antagonists. WO2002076926; 2002
   Google Scholar
• Taveras AG, Aki CJ, Bond RW, et al. Preparation of 3,4-di-substituted cyclobutene-1,2-diones as cxc – chemokine receptor ligands. WO2002083624; 2002
   Google Scholar
• Gonsiorek W, Fan X, Hesk D, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharm Exp Ther 2007;322:477-85
   PubMed Web of Science ®Google Scholar
• Chapman RW, Minnicozzi M, Celly C, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharm Exp Ther 2007;322:486-93
   PubMed Web of Science ®Google Scholar
• Kanniess F, Khalilieh S, Ludwig-Sengpiel A, et al. SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects European Respiratory Symposium, September 2007. Eur Resp J 2007;30(Suppl 51):613s
   PubMedGoogle Scholar
• Taveras AG, Aki CJ, Chao J, et al. Preparation of 3,4-di(substituted amino)cyclobutene-1,2-diones as CXC – chemokine receptor ligands. WO2004011418; 2004
   Google Scholar
• Chao JH, Taveras AG, Chao JP, et al. C(4)-Alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. Bioorg Med Chem Lett 2007;17:3778-83
   PubMed Web of Science ®Google Scholar
• Dwyer MP, Yu Y, Chao JP, et al. Discovery of 2-Hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist. J Med Chem 2006;49:7603-6
   PubMed Web of Science ®Google Scholar
• McCleland BW, Davis RS, Palovich MR, et al. Comparison of N,N′-diarylsquaramides and N,N′-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett 2007;17:1713-7
   PubMed Web of Science ®Google Scholar
• Taveras AG, Chao J, Biju PJ, et al. Preparation of diaminothiadiazole dioxides and monoxides as CXC – and CC-chemokine receptor ligands. WO2004033440; 2004
   Google Scholar
• Taveras AG, Dwyer M, Ferreira JA, et al. Preparation of 3,4-disubstituted maleimide compounds as CXC – chemokine receptor antagonists. WO2003031440; 2003
   Google Scholar
• Taveras AG, Dwyer M, Chao J, et al. 4,5-Diamino-1,2,3,4-tetrahydro-3, 6-pyridazinediones as CXC chemokine receptor antagonists for treatment of inflammatory disorders and cancer. WO2003057676; 2003
   Google Scholar
• Biju PJ, Taveras AG, Yu Y, et al. Preparation of diaminothiadiazoles as CXC – and CC-chemokine receptor ligands. WO2005066147; 2005
   Google Scholar
• Taveras AG, Zheng J, Biju PJ, et al. Preparation of isothiazole dioxides as CXC – and CC-chemokine receptor ligands. WO2005068460; 2005
   Google Scholar
• Purakkattle BJ. Di-substituted oxadiazoles as CXC – chemokine receptor ligands. WO2007002764; 2007
   Google Scholar
• Purakkattle BJ. 5,6-Disubstituted oxadiazolopyrazines and thiadiazolopyrazines as CXC – chemokine ligands and their preparation, pharmaceutical compositions and use in the treatment of COPD. WO2007005403; 2007
   Google Scholar
• Biju P, Yu Y, Aki C, et al. Synthesis and SAR investigation of 3, 4-diamino derivatives of thiadiazole-1-oxides as CXCR1-CXCR2 dual antagonists. Abstracts of Papers, 234th ACS National Meeting; 2007 August; MEDI-377, Boston
   Google Scholar
• Anon. Novel pyrimidine-based CXCR2 chemokine receptor antagonists. Exp Opin Ther Patents 2004;14:1507-10
   Google Scholar